While the advent of third-generation therapies has dramatically changed the treatment paradigm for EGFR-mutated lung cancer, resistance to these agents inevitably emerges. Understanding resistance mechanisms and their genomic underpinnings is crucial for developing innovative strategies that are capable of meaningfully prolonging patient survival.

Original languageEnglish
Pages (from-to)6112-6114
Number of pages3
JournalClinical Cancer Research
Issue number24
StatePublished - Dec 15 2018


Dive into the research topics of 'Targeting resistance to targeted therapies: Combating a resilient foe'. Together they form a unique fingerprint.

Cite this